NeonMind Announces Consolidation
January 19, 2023 Oakville, Ontario – January 19, 2023: NeonMind Biosciences Inc. (CSE: NEON) (OTC Pink: NMDBF) (FRA:6UF0) (“NeonMind” or the “Company”) announces that, in
Investors
Latest News
NeonMind Announces Cancellation of Securities
January 11, 2023 Oakville, Ontario – January 11, 2023: NeonMind Biosciences Inc. (CSE: NEON) (FRA:6UF0) (“NeonMind” or the “Company”) announces that, in preparation for the
NeonMind Signs Agreement to complete Reverse Merger with Lancaster Lithium Inc.
December 14, 2022 Oakville, Ontario – December 14, 2022: NeonMind Biosciences Inc. (CSE: NEON) (FRA:6UF0) (“NeonMind” or the “Company”) is pleased to announce that it
NeonMind Announces Management Change
December 9, 2022 Oakville, Ontario – December 9, 2022: NeonMind Biosciences Inc. (CSE: NEON) (OTC Pink:NMDBF) (FSE:6UF) (“NeonMind” or the “Company”) announced today that Rob
Email Alerts
Sign up today and receive company updates straight to your inbox.
Company Overview
NeonMind is an integrated psychedelic drug development and wellness company focused on therapeutic uses of psychedelics to address public health needs including obesity, weight management and mental health. NeonMind has two operating divisions, a pharmaceutical division engaged in drug development research for the potential therapeutic uses of psychedelic compounds, and a medical services division focused on launching specialty mental health clinics that integrate psychedelic therapeutics into traditional psychotherapy settings.
Investor Contact Information
Company
NeonMind Biosciences Inc.
5 – 519 Dundas St. W.
Suite #511
Oakville, ON L6M 5K3
Canada
Investor Relations
T: +1 (705) 710-NEON /
+1 (705) 710-6366
Transfer Agent
Endeavor Trust Corporation
T: 604-559-8908
david@endeavortrust.com
English